Updates on Pipeline Developments, Facility Expansions, and Conference Calls - Research Report on Merck, UnitedHealth, Amgen,

Updates on Pipeline Developments, Facility Expansions, and Conference Calls -
   Research Report on Merck, UnitedHealth, Amgen, Baxter, and Charles River

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, September 27, 2013

NEW YORK, September 27, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Merck &
Co. Inc. (NYSE: MRK), UnitedHealth Group Inc. (NYSE: UNH), Amgen, Inc.
(NASDAQ: AMGN), Baxter International Inc. (NYSE: BAX), and Charles River
Laboratories (NYSE: CRL). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Merck & Co. Inc. Research Report

On September 23, 2013, Merck & Co. Inc. (Merck) announced that it has received
a Complete Response Letter from the US Food and Drug Administration (FDA) for
the resubmission of the New Drug Application for sugammadex sodium injection,
the Company's investigational medicine for the reversal of neuromuscular
blockade induced by rocoronium or vecuronium. Merck also stated that the FDA's
letter brought forth some concerns regarding the operational aspects of a
hypersensitivity study that the agency had requested in 2008. David Michelson,
M.D., Head of Global Neuroscience Clinical Development, Merck Research
Laboratories, said, "We believe sugammadex is an important innovation, and
will work closely with the FDA to bring this product to hospitals, surgeons,
anesthesia professionals and patients in the United States." The Company
further reported that it is evaluating the Complete Response Letter and
expects to determine a path forward in the near future. The Full Research
Report on Merck & Co. Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-25/MRK]

--

UnitedHealth Group Inc. Research Report

On September 24, 2013, UnitedHealth Group Inc. (UnitedHealth) announced that
the Company will release its Q3 2013 financial results on October 17, 2013,
before the market opens. The Company's President and CEO Stephen J. Hemsley
will host a teleconference at 8:45 a.m. ET to discuss the results with
analysts and investors. In a separate release on July 18, 2013, the Company
reaffirmed its full-year FY 2013 revenue guidance of approximately $122
billion and tightened its full-year FY 2013 net earnings to a range of $5.35
to $5.50 per share. According to Thomson Reuters I/B/E/S, analysts are
expecting UnitedHealth to report revenue of $122.5 billion and EPS of $5.44 in
full-year FY 2013. The Full Research Report on UnitedHealth Group Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-25/UNH]

--

Amgen, Inc. Research Report

On September 24, 2013, Amgen, Inc. (Amgen) announced that it has entered into
a memorandum of understanding (MOU) with ShanghaiTech University to form a
strategic partnership for the advancement of biopharmaceutical discovery and
translational research in China. Under the agreement, Amgen plans to open a
China research and development (R&D) center at ShanghaiTech University.
Further, under the terms of the MOU, Amgen will co-locate its China R&D Center
with ShanghaiTech University's two life science institutes: the Shanghai
Institute for Advanced Immunochemical Studies (SIAIS) and the iHuman
Institute. Sean E. Harper, M.D., Executive Vice President of Research and
Development at Amgen, said, "Amgen and ShanghaiTech University share mutual
goals of scientific excellence and rigor and will benefit from each other's
strength and expertise in advancing biopharmaceutical discovery in China.
Expansion into China is a business priority for Amgen and opening this R&D
center is another clear and important step forward in Amgen's commitment to
the China market." Amgen stated that it expects the China R&D center to be
fully operational in 2014. The Full Research Report on Amgen, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-09-25/AMGN]

--

Baxter International Inc. Research Report

On September 19, 2013, Baxter International Inc. (Baxter) announced that the
Company voluntarily recalled two of its Dual Luer Lock Caps (Product Code
2C6250, Lots 10043 and 10044) because of the presence of loose particulate
matter found in the packaging. The Company stated that particulate matter
entering the fluid path from the Luer Lock Caps may result in thrombotic and
embolic events, which include pulmonary embolism, myocardial infarction and
stroke. The Company has not received any complaints regarding the issue, but
maintains that embolic events may not be easily attributed to such particulate
matter. Baxter further informed that it has identified and resolved the root
cause of the issue, and the financial impact of the recall is not material.
Baxter reported that the US FDA categorized this as a Class I recall. The Full
Research Report on Baxter International Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-09-25/BAX]

--

Charles River Laboratories Research Report

On September 12, 2013, Charles River Laboratories (Charles River) announced
that it is relocating its European endotoxin and microbial detection services
to a larger facility in Ecully, France. The Company stated that its new site
offers a full range of both rapid microbiology systems based on the Endosafe
cartridge technology for endotoxin testing and Accugenix microbial
identification services. In addition, the Company announced the opening of the
Charles River Accugenix contract laboratory service in Seoul, South Korea.
According to Charles River, this new location will initially offer DNA-based
sequencing of microorganisms, and will provide access to the Company's leading
library databases. The Full Research Report on Charles River Laboratories -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-25/CRL]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

InvestorsReports.com

SOURCE Investors' Reports

Contact: Kristi Saunders, +1-315-982-6420 (North America)
 
Press spacebar to pause and continue. Press esc to stop.